Integrin Alpha 7
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473971-integrin-alpha-7-itga7-pipeline-review-h1-2017
Summary
According to the recently published report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017'; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.
The report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017' outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.
Scope of the Report
- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 7 (ITGA7) - Overview
Integrin Alpha 7 (ITGA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 7 (ITGA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development
Strykagen Corp
Integrin Alpha 7 (ITGA7) - Drug Profiles
Stryka-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-234 - Drug Profile
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473971-integrin-alpha-7-itga7-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473971-integrin-alpha-7-itga7-pipeline-review-h1-2017
Summary
According to the recently published report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017'; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.
The report 'Integrin Alpha 7 (ITGA7) - Pipeline Review, H1 2017' outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.
Scope of the Report
- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 7 (ITGA7) - Overview
Integrin Alpha 7 (ITGA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 7 (ITGA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development
Strykagen Corp
Integrin Alpha 7 (ITGA7) - Drug Profiles
Stryka-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-234 - Drug Profile
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1473971-integrin-alpha-7-itga7-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
